In this study, we evaluated the activity of ETB in different infection models and it showed an excellent therapeutic effect against Mab. As shown in Table 1 and Table 2, survival of Mab was greatly reduced after ETB treatment in all the Mab strains tested in vitro, including Mab CIP 104536T S- and R-variants and clinical isolates at a IC50 range of 0.29–2.75 μM. The gene discussed is EDNRB; the disease is infection.